Celcuity Plans $400 Million Convertible Senior Notes Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 47 minutes ago
0mins
Source: seekingalpha
- Financing Plan: Celcuity announced its intention to offer $400 million of convertible senior notes due in 2032, aimed at providing funding support for the company's operations and R&D.
- Over-Allotment Option: The company will grant underwriters a 30-day option to purchase up to an additional $60 million of notes to meet market demand, enhancing the offering's flexibility.
- Use of Proceeds: The net proceeds from this offering will be used to repay all outstanding obligations under its loan agreement with Oxford Finance, as well as for clinical trials, commercialization activities, and other general corporate purposes.
- Market Condition Impact: Celcuity noted that the completion of the offering remains subject to market and other conditions, with no assurances regarding the timing, size, or final terms of the offering.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CELC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CELC
Wall Street analysts forecast CELC stock price to fall
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 122.960
Low
94.00
Averages
106.50
High
126.00
Current: 122.960
Low
94.00
Averages
106.50
High
126.00
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Celcuity Shares Drop Over 20% After Phase 3 Trial Data Release
- Trial Results Impact: Celcuity's stock plummeted over 20% on Tuesday following the release of detailed data from the VIKTORIA-1 Phase 3 trial, which, while achieving its primary endpoint of progression-free survival, revealed a Grade 5 treatment-related adverse event, raising significant safety concerns among investors.
- Adverse Event Analysis: Among the 350 patients, approximately 3% in the gedatolisib-triplet group discontinued due to treatment-related adverse events, compared to 4% in the gedatolisib-doublet group and 7% in the alpelisib plus fulvestrant group, indicating varying safety profiles across treatment combinations.
- Survival Comparison: Patients receiving the gedatolisib doublet had a median progression-free survival of 11.3 months, significantly longer than the 5.6 months for those on the alpelisib plus fulvestrant regimen, suggesting a notable therapeutic advantage that could influence future treatment decisions.
- Market Reaction and Outlook: The results are set to be presented at the ongoing ASCO meeting, and Celcuity's market outlook hinges on the FDA's decision regarding gedatolisib, expected on July 17; a favorable outcome could potentially reverse the current stock decline.
See More
Celcuity Plans $400 Million Convertible Senior Notes Offering
- Financing Plan: Celcuity announced its intention to offer $400 million of convertible senior notes due in 2032, aimed at providing funding support for the company's operations and R&D.
- Over-Allotment Option: The company will grant underwriters a 30-day option to purchase up to an additional $60 million of notes to meet market demand, enhancing the offering's flexibility.
- Use of Proceeds: The net proceeds from this offering will be used to repay all outstanding obligations under its loan agreement with Oxford Finance, as well as for clinical trials, commercialization activities, and other general corporate purposes.
- Market Condition Impact: Celcuity noted that the completion of the offering remains subject to market and other conditions, with no assurances regarding the timing, size, or final terms of the offering.
See More
Celcuity Proposes $400 Million Convertible Notes Offering
- Offering Size: Celcuity is proposing a public offering of $400 million in convertible senior notes, with an additional $60 million option for underwriters to cover over-allotments, indicating a strong market demand expectation from the company.
- Use of Proceeds: The net proceeds from this offering will be utilized to fully repay all outstanding obligations under its loan agreement with Oxford Finance, while the remainder will support clinical trials, commercialization, and R&D, enhancing the company's financial flexibility and competitive positioning.
- Bond Terms: The convertible notes will be general, unsecured senior obligations of the company, with interest payable semi-annually and a maturity date of August 1, 2032, allowing for flexible capital structure options as the company can choose cash, common stock, or a combination upon conversion.
- Market Conditions: The closing of the offering is subject to market and other conditions, and while uncertainties exist, Celcuity's strategic financing plan reflects its ongoing development potential in the biotechnology sector and confidence in future growth opportunities.
See More
Celcuity's Drug Trial Results Show Significant Efficacy
- Clinical Trial Results: Celcuity's experimental drug gedatolisib demonstrated a 50% reduction in the risk of disease progression or death in late-stage breast cancer patients, marking the first Phase 3 trial where this drug class clearly outperformed another, despite concerns over patient deaths.
- Survival Data: In patients with PIK3CA mutations, the median progression-free survival for the gedatolisib triplet and doublet therapies reached 11.1 months and 11.3 months respectively, significantly higher than the standard treatment's 5.6 months, indicating its potential to extend patient survival.
- Safety Analysis: While there were treatment-related deaths, the safety profile of gedatolisib remained consistent with earlier data, with serious side effects occurring in only 2.6% and 3.8% of patients in the triplet and doublet groups, respectively, compared to 7.1% in the standard treatment group.
- Market Reaction: Despite a 26% drop in stock price due to death reports, retail sentiment around CELC shifted from 'neutral' to 'extremely bullish', reflecting optimism towards the upcoming FDA decision, with CELC stock gaining approximately 687% over the past 12 months.
See More
Celcuity to Host Conference Call on VIKTORIA-1 Clinical Trial Results
- Clinical Trial Results Announcement: Celcuity plans to host a conference call on June 2, 2026, to discuss results from the PIK3CA mutant cohort of the VIKTORIA-1 clinical trial, which is expected to provide critical data for investors and the medical community.
- Lead Therapeutic Candidate: The company's lead therapeutic candidate, gedatolisib, acts as a kinase inhibitor of the PI3K/AKT/mTOR pathway, featuring a unique mechanism of action that may offer significant advantages in treating various solid tumors.
- Clinical Trial Progress: The VIKTORIA-1 trial evaluates the efficacy of gedatolisib in combination with fulvestrant, particularly in patients with hormone receptor-positive, HER2-negative advanced breast cancer, showing potential effectiveness against PIK3CA mutant tumors.
- Future Research Directions: Celcuity is also conducting the VIKTORIA-2 trial, assessing different treatment combinations for both endocrine-resistant and sensitive breast cancer patients, highlighting the company's ongoing innovation and growth potential in oncology treatment.
See More
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026 for an estimated $17.55 million, indicating strong confidence in the company, particularly as its stock has surged 250% over the past year.
- Quarter-End Position Value: As of March 31, 2026, Boxer Capital's position in Corvus was valued at $16.09 million, reflecting an active investment strategy amidst stock price fluctuations, further solidifying its standing in the biotech sector.
- Financial Overview: Corvus Pharmaceuticals ended Q1 2026 with $236.7 million in cash and marketable securities, with management stating that this funding will support operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: Corvus is conducting a Phase 2 trial expected to enroll approximately 200 patients, with preliminary data showing that 75% of patients maintained effective responses after treatment cessation, indicating potential in immune modulation that may attract further investor interest.
See More
Celcuity Shares Drop Over 20% After Phase 3 Trial Data Release
- Trial Results Impact: Celcuity's stock plummeted over 20% on Tuesday following the release of detailed data from the VIKTORIA-1 Phase 3 trial, which, while achieving its primary endpoint of progression-free survival, revealed a Grade 5 treatment-related adverse event, raising significant safety concerns among investors.
- Adverse Event Analysis: Among the 350 patients, approximately 3% in the gedatolisib-triplet group discontinued due to treatment-related adverse events, compared to 4% in the gedatolisib-doublet group and 7% in the alpelisib plus fulvestrant group, indicating varying safety profiles across treatment combinations.
- Survival Comparison: Patients receiving the gedatolisib doublet had a median progression-free survival of 11.3 months, significantly longer than the 5.6 months for those on the alpelisib plus fulvestrant regimen, suggesting a notable therapeutic advantage that could influence future treatment decisions.
- Market Reaction and Outlook: The results are set to be presented at the ongoing ASCO meeting, and Celcuity's market outlook hinges on the FDA's decision regarding gedatolisib, expected on July 17; a favorable outcome could potentially reverse the current stock decline.
See More
Celcuity Plans $400 Million Convertible Senior Notes Offering
- Financing Plan: Celcuity announced its intention to offer $400 million of convertible senior notes due in 2032, aimed at providing funding support for the company's operations and R&D.
- Over-Allotment Option: The company will grant underwriters a 30-day option to purchase up to an additional $60 million of notes to meet market demand, enhancing the offering's flexibility.
- Use of Proceeds: The net proceeds from this offering will be used to repay all outstanding obligations under its loan agreement with Oxford Finance, as well as for clinical trials, commercialization activities, and other general corporate purposes.
- Market Condition Impact: Celcuity noted that the completion of the offering remains subject to market and other conditions, with no assurances regarding the timing, size, or final terms of the offering.
See More
Celcuity Proposes $400 Million Convertible Notes Offering
- Offering Size: Celcuity is proposing a public offering of $400 million in convertible senior notes, with an additional $60 million option for underwriters to cover over-allotments, indicating a strong market demand expectation from the company.
- Use of Proceeds: The net proceeds from this offering will be utilized to fully repay all outstanding obligations under its loan agreement with Oxford Finance, while the remainder will support clinical trials, commercialization, and R&D, enhancing the company's financial flexibility and competitive positioning.
- Bond Terms: The convertible notes will be general, unsecured senior obligations of the company, with interest payable semi-annually and a maturity date of August 1, 2032, allowing for flexible capital structure options as the company can choose cash, common stock, or a combination upon conversion.
- Market Conditions: The closing of the offering is subject to market and other conditions, and while uncertainties exist, Celcuity's strategic financing plan reflects its ongoing development potential in the biotechnology sector and confidence in future growth opportunities.
See More
Celcuity's Drug Trial Results Show Significant Efficacy
- Clinical Trial Results: Celcuity's experimental drug gedatolisib demonstrated a 50% reduction in the risk of disease progression or death in late-stage breast cancer patients, marking the first Phase 3 trial where this drug class clearly outperformed another, despite concerns over patient deaths.
- Survival Data: In patients with PIK3CA mutations, the median progression-free survival for the gedatolisib triplet and doublet therapies reached 11.1 months and 11.3 months respectively, significantly higher than the standard treatment's 5.6 months, indicating its potential to extend patient survival.
- Safety Analysis: While there were treatment-related deaths, the safety profile of gedatolisib remained consistent with earlier data, with serious side effects occurring in only 2.6% and 3.8% of patients in the triplet and doublet groups, respectively, compared to 7.1% in the standard treatment group.
- Market Reaction: Despite a 26% drop in stock price due to death reports, retail sentiment around CELC shifted from 'neutral' to 'extremely bullish', reflecting optimism towards the upcoming FDA decision, with CELC stock gaining approximately 687% over the past 12 months.
See More
Celcuity to Host Conference Call on VIKTORIA-1 Clinical Trial Results
- Clinical Trial Results Announcement: Celcuity plans to host a conference call on June 2, 2026, to discuss results from the PIK3CA mutant cohort of the VIKTORIA-1 clinical trial, which is expected to provide critical data for investors and the medical community.
- Lead Therapeutic Candidate: The company's lead therapeutic candidate, gedatolisib, acts as a kinase inhibitor of the PI3K/AKT/mTOR pathway, featuring a unique mechanism of action that may offer significant advantages in treating various solid tumors.
- Clinical Trial Progress: The VIKTORIA-1 trial evaluates the efficacy of gedatolisib in combination with fulvestrant, particularly in patients with hormone receptor-positive, HER2-negative advanced breast cancer, showing potential effectiveness against PIK3CA mutant tumors.
- Future Research Directions: Celcuity is also conducting the VIKTORIA-2 trial, assessing different treatment combinations for both endocrine-resistant and sensitive breast cancer patients, highlighting the company's ongoing innovation and growth potential in oncology treatment.
See More
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026 for an estimated $17.55 million, indicating strong confidence in the company, particularly as its stock has surged 250% over the past year.
- Quarter-End Position Value: As of March 31, 2026, Boxer Capital's position in Corvus was valued at $16.09 million, reflecting an active investment strategy amidst stock price fluctuations, further solidifying its standing in the biotech sector.
- Financial Overview: Corvus Pharmaceuticals ended Q1 2026 with $236.7 million in cash and marketable securities, with management stating that this funding will support operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: Corvus is conducting a Phase 2 trial expected to enroll approximately 200 patients, with preliminary data showing that 75% of patients maintained effective responses after treatment cessation, indicating potential in immune modulation that may attract further investor interest.
See More
